biostudies-literatureUnknown48(11)Sinn M<p>Introduction: Cancer-associated venous thromboembolism (CAT) is a frequent and medical relevant problem. Guidelines recommend treatment with low molecular weight heparins (LMWH) or direct oral factor-Xa inhibitors as rivaroxaban for ≥3 months. Patient's preference and convenience is an important factor to guide treatment decision and to support treatment adherence. No data are available so far about patient-reported outcome in CAT.<h4>Methods</h4>CONKO-011/AIO-SUP-0115/ass. was an open-label, prospective, multicenter German phase III trial for cancer patients with newly diagnosed venous thromboembolism (VTE) randomized to rivaroxaban (Riva) or site-specific LMWH. Primary endpoint was patient-reported treatment satisfaction, measured by the Anti-Clot Treatment Scale (ACTS). The 12-item AOncology research and treatment685-695https://www.ebi.ac.uk/biostudies/studies/S-EPMC12237281biostudies-literatureCONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism.PMC12237281Pelzer UStriefler JKRiess HHellmann MRoderburg CTrappe RUSudhoff TSchlenska-Lange AWernecke KDMohamed OSemrau SLohneis AHeinz JEttrich TJKrziwanie ASinn MChristoph DCfalseCONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism.<p>Introduction: Cancer-associated venous thromboembolism (CAT) is a frequent and medical relevant problem. Guidelines recommend treatment with low molecular weight heparins (LMWH) or direct oral factor-Xa inhibitors as rivaroxaban for ≥3 months. Patient's preference and convenience is an important factor to guide treatment decision and to support treatment adherence. No data are available so far about patient-reported outcome in CAT.<h4>Methods</h4>CONKO-011/AIO-SUP-0115/ass. was an open-label, prospective, multicenter German phase III trial for cancer patients with newly diagnosed venous thromboembolism (VTE) randomized to rivaroxaban (Riva) or site-specific LMWH. Primary endpoint was patient-reported treatment satisfaction, measured by the Anti-Clot Treatment Scale (ACTS). The 12-item A2025-01-01T00:00:00Z20252026-06-06T17:23:53.198Z2026-06-03T03:10:16.292ZS-EPMC122372814041892410.1159/000545976